Viscosupplementation, so intra-articular injection of HA, is scientifically and clinically approved practice for reducing joint pain, improving functional condition of OA-affected joint, finally delaying the progression of the disease¹.

Biolevox™ HA 2.2% contains a high dose of 44 mg sodium hyaluronate in a 2 mL volume injection. This optimal 2.2% concentration of hyaluronate provides precise selected viscosity, tailored in the range of 250-300 Pa*s, which is dedicated for a triple injection therapy. Hyaluronate contained in Biolevox™ HA 2.2% is characterized with optimally high molecular weight of molecules contained that stays in the range of 1400 to 2400 kDa.

{|blog_list|}

HA-based gel with such unique properties improves shock absorption and lubrication of the cartilaginous surfaces as well as reduces inflammation state due to appropriate biological response via CD44 receptors. Moreover, such content is particularly tailored for a triple intra-articular HA treatment, providing long term clinical effect in OA patients^2,3.  

Therapy based on Biolevox™ HA 2.2% is perfectly safe as hyaluronan contained in the product is manufactured in fully controllable conditions by bacterial fermentation with use of Streptococcus sp. strain., providing the products that possess no possibility for uncontrolled tissue response upon the intra-articular injection^2,4.

The administration of Biolevox™ HA 2.2% is recommended as triple intra-articular therapy. Clinical data show that three consecutive intra-articular injections of hyaluronic acid gel with appropriately selected properties, like one of Biolevox™ HA with seven days intervals are clinically effective in ameliorating OA symptoms for at least 6 months⁵.

Package of Biolevox™ HA 2.2% contains single pre-filled syringe of 2 mL. 

The product is meant to be used by medical practitioners only.

Hyaluronic acid (HA) is one of the major constituent of articular cartilage extracellular matrix and synovial fluid¹. HA is a biopolysacharide - it consists of a number of sugar molecules bonded together into a long chain¹.

HA is a crucial structural component of synovial joint as it acts as a lubricant, shock absorber, filler and metabolic agent². OA development diminishes lubricating and shock absorption abilities of synovial fluid mainly by degradation of naturally produced HA³.

Viscosupplementation, so intra-articular injection of HA, is scientifically and clinically approved practice for reducing joint pain, improving functional condition of OA-affected joint, protecting cartilage and finally delaying progression of the disease⁴.

{|blog_list|}

Intra-articular injection of HA restores and maintains viscoelastic properties of synovial fluid, thus enables improved lubrication and relieves pain⁵. HA exerts anti-inflammatory, analgesic and chondroprotective effects in synovial joints⁶. In long term, clinical benefits of viscosupplementation persist well beyond the intraarticular residence of HA since clinical benefits achieved by HA intra-articular injection occurs due to increase of naturally produced HA in synovial joint thus reestablishment of joint homeostasis³. In consequence, viscosupplementation can improve joint function, thus allow return to normal physical activity and improve patient's quality of life⁷.

Importantly, many scientific comparisons and clinical investigations show that intra-articular HA injection is comprehensively safe, in contrast to steroid intra-articular injection that can lead to cartilage thinning and damage⁸.